Albany, NY -- (SBWIRE) -- 08/30/2018 -- Acromegaly is a rare but serious hormonal disorder caused by the excessive growth hormone (GH) in the body. The excessive GH usually comes from benign, or noncancerous, tumours in the pituitary, known as pituitary adenoma. This condition is the most often diagnosed in middle-aged adults, though the symptoms can appear at any age. In most of the cases, it is treatable, but because of its slow and sneaky onset, the disease remains undiagnosed. If left untreated, the disease can result in serious illness and premature death. The serious health complications are Type 2 diabetes, high blood pressure, increased risk of cardiovascular disease, and arthritis. The condition affects males and females in equal numbers.

Gigantism is excessive production of GH in children that is extremely rare and leads to exaggerated bone growth and an abnormal increase in height. It results due to excessive action of insulin like growth factor I (IGF-I) while the epiphyseal growth plates are open during childhood. This disease refers to excess GH secretion that occurs during childhood when growth plates are open, leading to accelerated vertical growth. This is in contrast to acromegaly, in which GH hyper secretion occurs after epiphyseal plate closure and stature is not affected. During adolescence, vertical growth is aggravated by hypogonadotropic hypogonadism and the resulting lack of gonadal steroids, which delays epiphyseal closure. True gigantism is rare and usually caused by a pituitary mammosomatotroph adenoma.

According to the report of DelveInsight "Acromegaly and Gigantism Therapeutics Market Insights, Epidemiology and Market Forecast- 2027" Acromegaly occurs in approximately 50 to 70 people per million and 3 out of every 1 million develop the disorder each year. The disease mostly occurs during the fourth and fifth decades. The mean age of diagnosis in male and female is 40 and 45 years respectively. A literature review of population studies from various geographical areas suggested the total prevalence ranging between 2.8 and 13.7 cases per 100,000 people, while annual incidence was reported to be in between 0.2 and 1.1 cases/100,000 people. The disease can occur at any stage after puberty, in case when excessive secretion of growth hormone occurs before puberty then this condition is known as gigantism, which is extremely rare. In one series of 2,367 children and adolescents with a pituitary adenoma, pituitary gigantism was found in only 0.6%. Boys and girls are equally affected.

Market Outlook of Acromegaly and Gigantism Market

Management of Acromegaly and Gigantism includes surgical removal of the tumor, medical therapy, and radiation therapy of the pituitary. Medical therapies such as Somatostatin analogs (SSAs), dopamine analogues and GH receptor antagonists are used to when primary surgery fails to induce complete remission. The market size of Acromegaly and Gigantism is expected to grow due to increasing prevalence of disease owing to increase in the tumor cases as well as awareness among people. Other market drivers will be the increased use of somatostatin analogs with better administration or dosing regimens and the treatment of refractory patient segments. Additionally, launches of upcoming therapies will also contribute to the overall growth of the market during the forecast period of 2018-2027. The emerging companies in this space are majorly focusing on developing novel drug delivery methods, rather than the exploration of new mechanisms of action.

The report covers the descriptive overview of Acromegaly and Gigantism explaining its pathophysiology, disease classification, diagnostic approaches and treatment algorithm. The report provides the insight into the epidemiology of the disease and its treatment in the 7 MM covering the United States, EU5 (Germany, Spain, France, Italy, UK) and Japan The report is a comprehensive account of both the current and emerging therapies covering the impact of the new therapies on the current treatment landscape. The report also reviews the detailed historical and forecasted Acromegaly and Gigantism market size covering the drug outreach in 7MM. The report provides the understanding of the future competition in Acromegaly and Gigantism by reviewing the market drivers and barriers.

For Sample Pages : https://www.delveinsight.com/report-store/acromegaly-and-gigantism-therapeutics-market-insight-epidemiology-and-market-forecast

Reasons to buy:
1. The report will help in developing business strategies by understanding trends shaping and driving the Acromegaly and Gigantism market.
2. To understand the future market competition in the Acromegaly and Gigantism market and Insight reviews of the key market drivers and barriers.
3. Identification of strong upcoming players in the Acromegaly and Gigantism market will help in devising strategies that will help in getting ahead of competitors.
4. In-depth understanding of the pipeline development and recent happenings will provide a competitive edge over competitors.

Companies Covered:

1. Chiasma
2. Camurus
3. Antisense Therapeutics
And many others……………

Table of contents

1. Report Introduction
2. Acromegaly and Gigantism Market Overview at a Glance
3. Disease Background and Overview: Acromegaly and Gigantism
4. Epidemiology and Patient Population
4.1. United States
4.2. EU-5
4.3. France
4.4. Italy
4.5. Spain
4.6. United Kingdom
4.7. Japan
5. Treatments Algorithm
5.1. United States
5.2. Europe
5.3. Japan
6. Marketed Products
6.2. Sandostatin LAR: Novartis
7. Emerging Therapies
7.1. Key Cross Competition
7.2. Mycapssa: Chiasma, Inc.
7.3. ATL-1103: Antisense Therapeutics
7.4. CAM2029: Camurus
8. 7MM Acromegaly and Gigantism: Country-Wise Market Analysis
8.1. United States Market Size
8.2. Germany Market Size
8.3. France Market Size
8.4. United Kingdom Market Size
8.5. Spain Market Size
8.6. Italy Market Size
8.7. Japan Market Size
9. Report Methodology
9.1. Sources Used
10. DelveInsight Capabilities
11. Disclaimer

*** For detailed TOC request for sample pages.

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. We support companies by providing end-to-end comprehensive solutions to improve their performance and in making long lasting decision for their businesses

We advise leading decision makers on their critical issues and opportunities; Research & Development, Strategy Making, Commercial, Operations, Competitive Intelligence, Competitive Landscaping and Mergers & Acquisition across all the Pharma and Biotech industries and geographies. We serve our clients by delivering practical and enduring results, and equipping our clients to grow and lead.